Claims for Patent: 6,683,155

Summary for Patent: 6,683,155

Title:	Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods
Abstract:	The present invention reveals a class of novel inhibitors of metalloproteinase. For convenience, these polypeptides are referred to as \"TIMP-3\", as these polypeptides represent a new class of members of the tissue inhibitors of metalloproteinases. Also provided are DNA sequences coding for all or part of the TIMP-3s, vectors containing such DNA sequences, and host cells transformed or transfected with such vectors. In addition, methods of producing recombinant TIMP-3s, methods of treating disorders, pharmaceutical compositions including TIMP-3s and antibodies selectively binding TIMP-3s are provided.
Inventor(s):	Silbiger; Scott M. (Woodland Hills, CA), Koski; Raymond A. (Old Lyme Road, CT)
Assignee:	Amgen Inc. (Thousand Oaks, CA)
Application Number:	08/728,160
Patent Claims:	1. A purified and isolated polypeptide comprising the amino acid sequence SEQ ID NO: 13. 2. A purified and isolated polypeptide comprising the amino acid sequence of amino acids 24-211 of SEQ ID NO: 13, optionally having a methionyl residue at position 23 of SEQ ID NO: 13. 3. A polypeptide product of expression of an exogenous nongenomic DNA sequence in a prokaryotic or eukaryotic host cell, wherein said DNA sequence encodes a human TIMP-3 polypeptide selected from the group consisting of: a) a polypeptide comprising amino acids 1 to 211 of SEQ ID NO: 13; b) a polypeptide comprising amino acids 24 to 211 of SEQ ID NO: 13; c) a polypeptide comprising amino acids 24 to 144 of SEQ ID NO: 13, and optionally, at the C-terminus, all or part of amino acids 145 to 211 of SEQ ID NO: 13; and d) a polypeptide of (b) or (c) comprising a methionyl group at position 23 of SEQ ID NO 13. 4. A composition comprising purified and isolated human TIMP-3 in a physiologically acceptable diluent, adjuvant or carrier, wherein said TIMP-3 is a polypeptide selected from the group consisting of: a) a polypeptide comprising amino acids 1 to 211 of SEQ ID NO: 13; b) a polypeptide comprising amino acids 24 to 211 of SEQ ID NO: 13; c) a polypeptide comprising amino acids 24 to 144 of SEQ ID NO: 13, and optionally, at the C-terminus, all or part of amino acids 145 to 211 of SEQ ID NO: 13; and d) a polypeptide of (b) or (c) comprising a methionyl group at position 23 of SEQ ID NO: 13. 5. A kit comprising a preparation of human TIMP-3 and one or more additional compositions beneficial for regulating degradation of extracellular matrix, wherein said TIMP-3 is a polypeptide selected from the group consisting of: a) a polypeptide comprising amino acids 1 to 211 of SEQ ID NO: 13; b) a polypeptide comprising amino acids 24 to 211 of SEQ ID NO: 13; c) a polypeptide comprising amino acids 24 to 144 of SEQ ID NO: 13, and optionally, at the C-terminus, all or part of amino acids 145 to 211 of SEQ ID NO: 13; and d) a polypeptide of (b) or (c) comprising a methionyl group at position 23 of SEQ ID NO: 13. 6. The kit of claim 5 wherein said additional composition is selected from the group consisting of: metalloproteinases, serine proteases, inhibitors of matrix degrading enzymes, intracellular enzymes, cell adhesion modulators, and factors regulating the expression of extracellular matrix degrading proteinases and their inhibitors. 7. The kit of claim 6 wherein said additional composition is selected from the group consisting of collagenases, polymorphonuclear leukocyte (PMN) collagenase, stromelysin I, stromelysin II/transin, matrilysin, invadolysin, putative metalloproteinase (PUMP-1), urokinase type plasminogen activator (UPA), tissue plasminogen activator (TPA), and plasmin. 8. The kit of claim 6 wherein said additional composition is selected from the group consisting of .alpha..sub.2 -macroglobulin, pregnancy zone protein, ovostatin, .alpha..sub.1 -proteinase inhibitor, .alpha..sub.2 -antiplasmin, aprotinin, protease nexin-1, plasminogen activator inhibitor (PAI)-1, PAI-2, TIMP-1 and TIMP-2. 9. The kit of claim 6 wherein said additional composition is selected from the group consisting of lysozomal enzymes, glycosidases and cathepsins. 10. The kit of claim 6 wherein said additional composition is a cell adhesion modulator. 11. The kit of claim 6 wherein said additional composition is a factor regulating expression of extracellular matrix degrading proteinases and their inhibitors. 12. The kit of claim 6 wherein said additional composition is selected from the group consisting of an interleukin, tumor necrosis factor .alpha. (TNF.alpha.), transforming growth factor .beta. (TGF-.beta.), glucocorticoids, retinoids, erythropoietin (EPO), stem cell factor (SCF), macrophage colony stimulating factor (M-CSF), insulin like growth factor (IGF)-I, IGF-II, epidermal growth factor (EGF), a fibroblast growth factor (FGF), keratinocyte growth factor (KGF), platelet derived growth factor (PDGF), an interferon, protein kinase C, and inositol phosphatases. 13. The kit of claim 5 wherein said additional composition is selected from the group consisting of E-selectins, integrins, L-selectins, chemokines, and chemoattractants. 14. The kit of claim 5 wherein said additional composition is selected from the group consisting of brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT-3), nerve growth factor (NGF), ciliary neurotrophic factor (CNTF), and neu differentiation factor (NDF). 15. A mature human TIMP-3 polypeptide according to amino acids 24-211 of SEQ ID NO: 13, optionally lacking one or more C-terminal cysteine residues at positions 145,150, 155, 163,184 and 192. 16. The polypeptide product of claim 3, which binds to a zinc binding domain of collegenase. 17. The polypeptide according to claim 15, having a methionyl residue at position 23 of SEQ ID NO: 13.

Details for Patent 6,683,155

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bayer Healthcare Pharmaceuticals Inc.	TRASYLOL	aprotinin	Injection	020304	12/29/1993		2013-10-06
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846	01/16/1978		2013-10-06
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2013-10-06